BMS Names New Board Member
Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.
Bristol-Myers Squibb’s board of directors has elected Thomas J. Lynch, Jr., MD to its board, effective Jan. 1, 2014. Lynch will serve as a member of the Science and Technology Committee of the Board of Directors.
Lynch is currently the director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven. He is also the Richard Sackler and Jonathan Sackler Professor of Medical Oncology at Yale-New Haven. He has held these positions since 2009. From 1993 to 2009, he was a professor of medicine at Harvard Medical School and chief of hematology and oncology at Massachusetts General Hospital (MGH) Cancer Center. He also served as director of the Center for Thoracic Cancers at MGH and director of medical oncology at the MGH Thoracic Oncology Center.
Source: Bristol-Myers Squibb
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
